Terms: = Kidney tumors AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Treatment
100 results:
1. Cancer-specific mortality in non-metastatic T1a renal cell carcinoma treated with radiotherapy versus partial nephrectomy.
de Angelis M; Morra S; Scheipner L; Siech C; Jannello LMI; Baudo A; Goyal JA; Tian Z; Longo N; Ahyai S; de Cobelli O; Chun FKH; Saad F; Shariat SF; Carmignani L; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2024 Mar; 42(1):193. PubMed ID: 38530480
[TBL] [Abstract] [Full Text] [Related]
2. Propofol Regulates HIF-1 α Effect of Expression of Targeted SIRT1 Signal pathway on kidney Renal Clear Cell Carcinoma.
Chen X; Li C; Zeng R; Qiu L; Huang J; Wang N; Ren X; Ling X
Cell Mol Biol (Noisy-le-grand); 2023 Mar; 69(3):145-149. PubMed ID: 37300675
[TBL] [Abstract] [Full Text] [Related]
3. Utilization of a Virtual Tumor Board for the Care of Patients With Renal Masses: Experience From a Quality Improvement Collaborative.
Hijazi MA; Prebay ZJ; Johnson A; Wilder S; Patel A; Mehra R; Montie JE; Noyes SL; Mirza M; Jafri M; Weizer A; Sarle R; Ghani KR; Rogers C; Lane BR
Urol Pract; 2023 Jul; 10(4):380-388. PubMed ID: 37103551
[TBL] [Abstract] [Full Text] [Related]
4. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Choueiri TK; Eto M; Motzer R; De Giorgi U; Buchler T; Basappa NS; Méndez-Vidal MJ; Tjulandin S; Hoon Park S; Melichar B; Hutson T; Alemany C; McGregor B; Powles T; Grünwald V; Alekseev B; Rha SY; Kopyltsov E; Kapoor A; Alonso Gordoa T; Goh JC; Staehler M; Merchan JR; Xie R; Perini RF; Mody K; McKenzie J; Porta CG
Lancet Oncol; 2023 Mar; 24(3):228-238. PubMed ID: 36858721
[TBL] [Abstract] [Full Text] [Related]
5. treatment and Implications of Vascular Endothelial Growth Factor Inhibitor-Induced Blood Pressure Rise: A Clinical Cohort Study.
van Dorst DCH; Kabadayi S; Oomen-de Hoop E; Danser AHJ; Mathijssen RHJ; Versmissen J
J Am Heart Assoc; 2023 Jan; 12(1):e028050. PubMed ID: 36583425
[TBL] [Abstract] [Full Text] [Related]
6. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Motzer R; Porta C; Alekseev B; Rha SY; Choueiri TK; Mendez-Vidal MJ; Hong SH; Kapoor A; Goh JC; Eto M; Bennett L; Wang J; Pan JJ; Saretsky TL; Perini RF; He CS; Mody K; Cella D
Lancet Oncol; 2022 Jun; 23(6):768-780. PubMed ID: 35489363
[TBL] [Abstract] [Full Text] [Related]
7. Safety and Efficacy of Bis-Glyceryl Ascorbate as Prophylaxis for Hand-Foot Skin Reaction: A Single-Arm, Open-Label Phase I/II Study (DGA Study).
Yamamoto K; Nishiyama S; Kunisada M; Iida M; Ito T; Ioroi T; Makimoto H; Omura T; Harada K; Fujisawa M; Nishigori C; Yano I
Oncologist; 2022 May; 27(5):e384-e392. PubMed ID: 35285503
[TBL] [Abstract] [Full Text] [Related]
8. Improvement in colorectal cancer outcomes over time is limited to patients with left-sided disease.
Rumpold H; Hackl M; Petzer A; Wolf D
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3007-3014. PubMed ID: 34977964
[TBL] [Abstract] [Full Text] [Related]
9. Renal Primitive Neuroectodermal Tumor With Inferior Vena Cava Thrombus: Case Series and Literature Review of a Rare but Challenging Entity.
Xu C; Sun Z; Xiao R; He W; Ma L
Clin Genitourin Cancer; 2021 Oct; 19(5):e273-e279. PubMed ID: 33941490
[TBL] [Abstract] [Full Text] [Related]
10. Cryoablation of renal tumors: long-term follow-up from a multicenter experience.
Stacul F; Sachs C; Giudici F; Bertolotto M; Rizzo M; Pavan N; Balestreri L; Lenardon O; Pinzani A; Pola L; Cicero C; Celia A; Cova MA
Abdom Radiol (NY); 2021 Sep; 46(9):4476-4488. PubMed ID: 33912986
[TBL] [Abstract] [Full Text] [Related]
11. Positively Charged Nanoparticle Delivery of n-Butylidenephthalide Enhances Antitumor Effect in Hepatocellular Carcinoma.
Chang KF; Huang XF; Lin YL; Liao KW; Hsieh MC; Chang JT; Tsai NM
Biomed Res Int; 2021; 2021():8817875. PubMed ID: 33791383
[TBL] [Abstract] [Full Text] [Related]
12. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK;
N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314
[TBL] [Abstract] [Full Text] [Related]
13. Effect of 4,5-diazafluorene derivative on γδ T cell-mediated cytotoxicity against renal cell carcinoma.
Wen X; Wu Y; Tanaka Y; Awadasseid A; Tao H; Zhang W
Life Sci; 2021 Mar; 269():119066. PubMed ID: 33460663
[TBL] [Abstract] [Full Text] [Related]
14. Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity.
Hermansen CK; Donskov F
J Geriatr Oncol; 2021 Jun; 12(5):827-833. PubMed ID: 33388280
[TBL] [Abstract] [Full Text] [Related]
15. Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance).
Chen RC; Choueiri TK; Feuilly M; Meng J; Lister J; Marteau F; Falchook AD; Morris MJ; George DJ; Feldman DR
Cancer; 2020 Dec; 126(24):5311-5318. PubMed ID: 33022096
[TBL] [Abstract] [Full Text] [Related]
16. Suppression of PKCδ/NF-κB Signaling and Apoptosis Induction through Extrinsic/Intrinsic Pathways Are Associated Magnolol-Inhibited Tumor Progression in Colorectal Cancer In Vitro and In Vivo.
Su CM; Weng YS; Kuan LY; Chen JH; Hsu FT
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429376
[TBL] [Abstract] [Full Text] [Related]
17. [Clinicopathologic features and prognostic analyses of locally recurrent renal cell carcinoma patients after initial surgery].
Tang Q; Lin RC; Yao L; Zhang Z; Hao H; Zhang CJ; Cai L; Li XS; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Aug; 51(4):628-631. PubMed ID: 31420612
[TBL] [Abstract] [Full Text] [Related]
18. Renal cell carcinoma in the Canadian Indigenous population.
Wong ECL; Breau RH; Mallick R; Wood L; Pouliot F; Basappa NS; Tanguay S; Soulières D; So A; Heng D; Lavallée LT; Drachenberg D; Kapoor A
Curr Oncol; 2019 Jun; 26(3):e367-e371. PubMed ID: 31285681
[TBL] [Abstract] [Full Text] [Related]
19. Bevacizumab plus IFN-alpha-2a in First-line treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study.
Schultze-Seemann W; Schulz H; Tschechne B; Häckl M
Anticancer Res; 2019 Feb; 39(2):875-882. PubMed ID: 30711970
[TBL] [Abstract] [Full Text] [Related]
20. Differential expression patterns of the short and long isoform of cFLIP on fasL‑mediated apoptosis.
Um HJ; Chauhan AK; Min KJ; Kwon TK
Oncol Rep; 2018 May; 39(5):2443-2449. PubMed ID: 29565452
[TBL] [Abstract] [Full Text] [Related]
[Next]
